For research use only. Not for therapeutic Use.
CD73-IN-3 is a potent CD73 inhibitor (IC50=7.3 nM in Calu6 human cell assay). CD73-IN-3, example 2 extracted from patent WO2019168744 A1, has the potential for cancer research[1].
CD73-IN-3 inhibits CD73 activity in human serum with an EC50 of 0.213 μM. CD73-IN-3 inhibits CD73 activity in human serum by 56.8%, 71.7% and 76.9% at 0.52 μM, 1.56 μM, 4.68 μM,respectively[1].In Calu6 human cell assay against CD73, the IC50 for CD73-IN-3 against CD73 is 0.0073 uM[1].
| Catalog Number | I031232 |
| CAS Number | 2375815-63-5 |
| Synonyms | 5-[6-methyl-5-[(1S,2R)-2-propan-2-ylcyclopropyl]pyridazin-3-yl]-1H-pyrimidine-2,4-dione |
| Molecular Formula | C15H18N4O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C15H18N4O2/c1-7(2)9-4-11(9)10-5-13(19-18-8(10)3)12-6-16-15(21)17-14(12)20/h5-7,9,11H,4H2,1-3H3,(H2,16,17,20,21)/t9-,11+/m1/s1 |
| InChIKey | WHRUIISQCORGKK-KOLCDFICSA-N |
| SMILES | CC1=NN=C(C=C1C2CC2C(C)C)C3=CNC(=O)NC3=O |
| Reference | [1]. Robert Dean Dally, et al. Cd73 inhibitors. Patent WO2019168744 A1. |
